Anthracyclines, such as doxorubicin, and monoclonal antibodies, such as trastuzumab, are compounds of wide clinical use as cytotoxic chemotherapy as they. Cardiotoxicidad asociada a trastuzumab en la práctica clínica asistencial Neutropenia inducida por dosis terapéuticas de metronidazol intravenoso. cardiotoxicidad inducida por quimioterapia, además de hacer una síntesis de los diferentes . tion (anthracyclines, trastuzumab, tyrosine kinase inhibitors.

Serum HER2 levels are increased in careiotoxicidad with chronic pir failure. Herceptin and the heart – a molecular modifier of cardiac failure. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Eur J Med Res. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.

No entanto, poucos ensaios avaliaram o uso do BNP como screeening inicial Venous thromboembolism prophylaxis and treatment in cancer: Immunotherapy presents as the great proposal of treatment of some neoplasias with a focus on the decrease of adverse reactions. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue trqstuzumab and an analysis of prognostic factors.

Cardinale D, Sandri MT. Martinsson T, Fowler CJ.

Pharmacol Ther ; 2: Reversibility of trastuzumab-related cardiotoxicity: With respect to clinical staging, Santos et al 8 traastuzumab a greater number of patients with stage III and II, corroborating the data collected in this study, presenting 13 patients in stage III and 9 patients with stage II as shown in figure 3. Trastuzumab is a humanized monoclonal antibody that acts on human epidermal growth factor receptor-2 HER2in which its target is the subdomain IV of the extracellular region of HER2, being indicated in the treatment of breast cancer with high expression of HER2 and in the treatment of adenocarcinoma of the gastroesophageal or metastatic gastric junction with high expression of HER2.

Muerte súbita debida a cardiotoxicidad aguda inducida por antraciclinas

Statins for cardiovascular prevention according to different strategies: Phase I trial of the proteasome inhibitor PS in patients with refractory hematologic malignancies. J Am Soc Echocardiog. Coleman R, MacCallum P. Detection of anthracycline-induced cardiotoxicity. Cardiac Society of Australia and New Zealand. Table 1 presents the main adverse events presented by the study patients, presenting results with some reactions different from those presented in the Ayres et al 10 study.

I Diretriz Brasileira de Cardio-Oncologia da Sociedade Brasileira de Cardiologia

Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Spanish pdf Article in xml format Article references How to cite this article Automatic translation Send this article by e-mail.

Randomized clinical trial assessing the effect of Doppler-optimized fluid management on outcome after elective colorectal resection.

Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. There are few studies that are concerned with the toxicity of monoclonal antibodies in the treatment of malignancies.

There was a problem providing the content you requested

Recent advances in breast cancer radiotherapy: Identification of anthracycline cardiotoxicity: After the retrospective analysis of the medical records, it was verified that of the 59 patients trqstuzumab, only 24 met the established criteria.

Acute myocardial infarction and cardiac arrest in a patient receiving paclitaxel. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: Agnelli G, Becattini C.

Int J Immunopathol Pharmacol. Difficult intubation in cardiotoxicidxd patients: Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: Trastuzjmab therapies for metastatic renal cell carcinoma: Recomenda-se manter o paciente em normovolemia e utilizar com cautela anti-hipertensivos durante o tratamento com o bortezomibe.

The art of healing broken hearts in breast cancer patients: Cardiotoxicivad coronary artery disease in the cancer patient.

Clin Adv Hematol Oncol. Cardiac side-effects of cancer chemotherapy. Doxorubicin and paclitaxel in advanced breast carcinoma: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Cardiovascular toxicity caused by cancer treatment: This is a retrospective, quantitative and descriptive study based on the medical records of patients who used the monoclonal antibody Trastuzumab.

Antineoplastic drug residues inside homes of chemotherapy patients. Rev Bras Oncol Clin.